Introduction
Malaria is a global public health threat, particularly in tropical and sub-tropical countries [1]. The majority of malaria episodes reported annually worldwide are from the Sub-Saharan African countries including Sudan [1,2]. Unfortunately, Sudan suffers from several infectious diseases with overlapping symptoms creating additional challenges in the case definition and management [3–6]. This delay in identifying the cases, reporting, and management is contributing to the increase of malaria burden [7–9]. In Sudan, the national malaria treatment guidelines recommend using Artesunate/Lumefantrine as a first-line treatment for uncomplicated falciparum malaria, and Artesunate or Quinine for treating the severe infections [10]. This case report presents a severe subconjunctival hemorrhage due to severe consecutive vomiting that was induced by the intake of artemether/lumefantrine for malaria treatment.